Professor Donald McDonald at San Francisco is one of the pioneers in vascular field and received several distinguished honors including Judah Folkman Memorial Lectureship. His laboratory has revealed cellular mechanisms of vascular and lymphatic changes involved in cancer and chronic inflammation and contributed to the understanding on the disease pathophysiology. Recent findings by his group include effects of oncolytic vaccinia virus infection of endothelial cells on tumor angiogenesis, tumor cell killing, invasion, and metastasis. He will talk about endothelial heterogeneity in normal and pathological contexts.
  • Chairperson
  • • Gou Young Koh (KAIST / IBS, Korea)
    • 09:20-10:00
  • Chairperson
  • • Hyo-Soo Kim (Seoul National University, Korea)
    • 10:00-10:40
    Professor Ralf Adams directing Max Planck Institute for Molecular Biomedicine at Muenster is one of the recognized investigators leading organotypic vascular morphogenesis. His group focuses on the vertebrate vascular system, in which blood vessels need to integrate precisely into different organ environments and retain plasticity allowing them to adapt to changing requirements and signals. Work of his laboratory has provided fundamental insight into the molecular regulation of angiogenesis and, in particular, the functional roles of endothelial cells and pericytes. Their studies have also contributed to the elucidation of disease processes and have identified the genetic cause of several human syndromes. He will update organ-specific and functional specialization of vascular cells.
  • Chairperson
  • • Young-Guen Kwon (Yonsei University, Korea)
    • 11:00-11:40
  • Chairperson
  • • Goo Taeg Oh (Ewha Womans University, Korea)
    • 11:40-12:20
    Professor Kari Alitalo directing translational cancer medicine research at Helsinki is a pioneer in vascular field. His group isolated and characterized the arterial endothelial tyrosine kinase Bmx, Tie1 angiopoietin receptor, lymphangiogenic receptor VEGFR3, and the first lymphangiogenic growth factor, VEGF-C, and characterized VEGF-B as a growth factor for coronary and adipose vasculature. His group demonstrated VEGF-C induced tumor lymphangiogenesis and metastasis, and inhibitors of the VEGFR-3 signal transduction pathway, which are in phase 2 clinical trials in age-related macular degeneration and diabetic macular edema, and developed growth factor therapy for lymphedema, which is now in phase 2 clinical trial. A recent finding by his laboratory was the discovery of meningeal lymphatic vessels. He will present recent findings on lymphagiogenesis mechanisms and translational approaches.
  • Chairperson
  • • Jun-Kyu Suh (Inha University, Korea)
    • 08:30-09:10
    Professor Mark Kahn at Philadelphia is a practicing cardiologist with a full-time laboratory that studies cardiovascular development and function. His lab has a long-standing interest in vascular biology and identified numerous players, including MEKK3-KLF2/4 signaling and PDCD10, and hemodynamic regulation that dictate blood and lymphatic vascular development and diseases. He will talk about his recent translational interests associated with cerebral cavernous malformation, deep venous thrombosis, and other vascular diseases.
  • Chairperson
  • • Kyu-Won Kim (Seoul National University, Korea)
    • 09:10-09:50
  • Chairperson
  • • Young Myeong Kim (Kangwon National University, Korea)
    • 13:30-14:10
  • Chairperson
  • • Ho Jeong Kwon (Yonsei University, Korea)
    • 08:30-09:10
  • Chairperson
  • • Jin Han (Inje University, Korea)
    • 09:10-09:50
  • Chairperson
  • • Hyo-Soo Kim (Seoul National University, Korea)
    • 16:50-17:30
  • Chairperson
  • • Joong Yeol Park (University of Ulsan, Korea)
    • 17:30-18:10
  • Chairperson
  • • Kyong Soo Park (Seoul National University, Korea)
  • Chairperson
  • • Sang Hong Back (The Catholic University of Korea, Korea)
    • 14:20-15:00